DE602004018788D1 - Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen - Google Patents

Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen

Info

Publication number
DE602004018788D1
DE602004018788D1 DE602004018788T DE602004018788T DE602004018788D1 DE 602004018788 D1 DE602004018788 D1 DE 602004018788D1 DE 602004018788 T DE602004018788 T DE 602004018788T DE 602004018788 T DE602004018788 T DE 602004018788T DE 602004018788 D1 DE602004018788 D1 DE 602004018788D1
Authority
DE
Germany
Prior art keywords
factor
specific antibodies
similar effect
ligands
show
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004018788T
Other languages
German (de)
English (en)
Inventor
Friedrich Scheiflinger
Randolf Kerschbaumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34273861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004018788(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of DE602004018788D1 publication Critical patent/DE602004018788D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004018788T 2003-09-12 2004-09-07 Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen Expired - Lifetime DE602004018788D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/661,366 US7297336B2 (en) 2003-09-12 2003-09-12 Factor IXa specific antibodies displaying factor VIIIa like activity
PCT/EP2004/009975 WO2005025615A2 (en) 2003-09-12 2004-09-07 FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY

Publications (1)

Publication Number Publication Date
DE602004018788D1 true DE602004018788D1 (de) 2009-02-12

Family

ID=34273861

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004018788T Expired - Lifetime DE602004018788D1 (de) 2003-09-12 2004-09-07 Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen

Country Status (9)

Country Link
US (1) US7297336B2 (enExample)
EP (1) EP1660536B1 (enExample)
JP (1) JP4887148B2 (enExample)
AT (1) ATE419277T1 (enExample)
AU (1) AU2004271706B2 (enExample)
CA (1) CA2538895A1 (enExample)
DE (1) DE602004018788D1 (enExample)
ES (1) ES2320665T3 (enExample)
WO (1) WO2005025615A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
EP1876236B9 (en) * 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
TR201802772T4 (tr) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
PL2902787T3 (pl) * 2012-09-28 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Sposób oceny reakcji krzepnięcia krwi
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
JP6606505B2 (ja) 2014-03-11 2019-11-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6954842B2 (ja) 2015-12-25 2021-10-27 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
JP7320943B2 (ja) 2016-04-28 2023-08-04 中外製薬株式会社 抗体含有製剤
CA3024485A1 (en) * 2016-05-16 2017-11-23 Baxalta Incorporated Anti-factor ix padua antibodies
BR112019003989A2 (pt) 2016-09-06 2019-05-28 Chugai Pharmaceutical Co Ltd métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado
US20190248920A1 (en) * 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
MX2019005772A (es) * 2016-11-23 2019-10-02 Bioverativ Therapeutics Inc Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
MY204354A (en) 2017-02-01 2024-08-24 Novo Nordisk As Procoagulant antibodies
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
UA128389C2 (uk) 2017-09-29 2024-07-03 Чугаі Сейяку Кабусікі Кайся Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
PE20211399A1 (es) * 2018-08-01 2021-07-27 Novo Nordisk As Anticuerpos procoagulantes mejorados
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CA3123177A1 (en) 2018-12-21 2020-06-25 Kymab Limited Fixaxfx bispecific antibody with common light chain
WO2021152066A1 (en) 2020-01-30 2021-08-05 Novo Nordisk A/S Bispecific factor viii mimetic antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2152953T3 (es) 1992-08-27 2001-02-16 Sanquin Bloedvoorziening Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
CA2294833A1 (en) 1997-07-03 1999-01-14 Smithkline Beecham Corporation Crystal structures of anti-factor ix fab fragments and methods of use for peptidomimetic design
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
DK1383785T3 (da) * 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf

Also Published As

Publication number Publication date
AU2004271706B2 (en) 2010-09-02
EP1660536B1 (en) 2008-12-31
ATE419277T1 (de) 2009-01-15
WO2005025615A3 (en) 2005-06-02
CA2538895A1 (en) 2005-03-24
WO2005025615A2 (en) 2005-03-24
AU2004271706A1 (en) 2005-03-24
JP2007504812A (ja) 2007-03-08
ES2320665T3 (es) 2009-05-27
US20050058640A1 (en) 2005-03-17
US7297336B2 (en) 2007-11-20
JP4887148B2 (ja) 2012-02-29
EP1660536A2 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
DE602004018788D1 (de) Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
EA200700225A1 (ru) Аналоги тетрапептида
SE0301700D0 (sv) Novel compounds
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
BRPI0412989A (pt) combinação farmacêutica útil para mobilização de célula-tronco
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
ATE514718T1 (de) Peptabody für krebsbehandlung

Legal Events

Date Code Title Description
8363 Opposition against the patent